Our laboratory has previously shown that antagonism of 5-HT2B can reduce AV myofibroblast activation by repressing non-canonical TGF-β signaling in vitro [20], indicating that 5-HT2B may be a therapeutic target for CAVD. The gene discussed is HTR2B; the disease is congenital bilateral aplasia of vas deferens from CFTR mutation.